Company / Operating Cash Flow per Share
Seres Therapeutics, Inc. Operating Cash Flow per Share History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$13.57
FY2025
5-year range
-$13.57 / $0.05
FY2021-FY2025
Trend
-25501.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share changed -25501% YoY in FY2025, a notable deviation from the 9-year average annual change of -2849%.
Based on SEC 10-K filings.
-13.57 in FY2025.
Declined from $-1.02 to $-13.57 over the past 3 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 25501.3% year-over-year.
- Peak operating cash flow per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$13.57 | -25501.3% |
| FY2023 | $0.05 | +105.2% |
| FY2022 | -$1.02 | -21.8% |
| FY2021 | -$0.84 | +6.6% |
| FY2020 | -$0.90 | +51.4% |
| FY2019 | -$1.84 | -270.4% |
| FY2018 | $1.08 | +207.0% |
| FY2017 | -$1.01 | -281.9% |
| FY2016 | -$0.27 | +65.7% |
| FY2015 | -$0.77 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026